Changing glucocorticoid action: 11β-hydroxysteroid dehydrogenase type 1 in acute and chronic inflammation.
The Journal of Steroid Biochemistry and Molecular Biology(2013)
摘要
Since the discovery of cortisone in the 1940s and its early success in treatment of rheumatoid arthritis, glucocorticoids have remained the mainstay of anti-inflammatory therapies. However, cortisone itself is intrinsically inert. To be effective, it requires conversion to cortisol, the active glucocorticoid, by the enzyme 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1). Despite the identification of 11 beta-HSD in liver in 1953 (which we now know to be 11 beta-HSD1), its physiological role has been little explored until recently. Over the past decade, however, it has become apparent that 11 beta-HSD1 plays an important role in shaping endogenous glucocorticoid action. Acute inflammation is more severe with 11 beta-HSD1-deficiency or inhibition, yet in some inflammatory settings such as obesity or diabetes, 11 beta-HSD1-deficiency/inhibition is beneficial, reducing inflammation. Current evidence suggests both beneficial and detrimental effects may result from 11 beta-HSD1 inhibition in chronic inflammatory disease. Here we review recent evidence pertaining to the role of 11 beta-HSD1 in inflammation. This article is part of a Special Issue entitled 'CSR 2013'. (C) 2013 Elsevier Ltd. All rights reserved.
更多查看译文
关键词
11β-HSD,H6PD,TNF-α,LPS,IL,C/EBP,NF-κB,EGR-1,HPA,MCP,VCAM
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要